RA

Rani Therapeutics Holdings IncNASDAQ RANI Stock Report

Last reporting period 30 Sep, 2023

Updated 18 Nov, 2024

Last price

Market cap $B

0.117

Micro

Exchange

XNAS - Nasdaq

RANI Stock Analysis

RA

Uncovered

Rani Therapeutics Holdings Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.117

Dividend yield

Shares outstanding

24.72 B

Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company. The Company’s technologies enable the development of orally administered biologics. The Company has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which delivers any drug, including molecules, such as peptides, proteins and antibodies. The RaniPill capsule delivers up to a three micrograms (mg) dose of the drug with high bioavailability. Its capsule includes a coating that is designed to withstand stomach acid but dissolves in the jejunum portion of the small intestine. The Company’s product candidate RaniPill capsule is in Phase I clinical trial. The Company’s RaniPill capsule is delivering a variety of biological therapeutics. Its pipeline includes core product candidate programs, such as RT-101, RT-105, RT-102, RT-109 and RT-110. The Company manufactures and assembles RaniPill capsules at its facilities in San Jose and Milpitas, California.

View Section: Eyestock Rating